Currently out of the existing stock ratings of Ian Somaiya, 57 are a BUY (71.25%), 23 are a HOLD (28.75%).

Ian Somaiya

Work Performance Price Targets & Ratings Chart

Analyst Ian Somaiya, carries an average stock price target met ratio of 69.01% that have a potential upside of 39.13% achieved within 631 days. Previously, Ian Somaiya worked at BMO, NOMURA.

Ian Somaiya’s has documented 168 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PTGX, Protagonist Therapeutics at 08-Mar-2018.

Wall Street Analyst Ian Somaiya

Analyst best performing recommendations are on INFI (INFINITY PHARMACEUTICALS).
The best stock recommendation documented was for INFI (INFINITY PHARMACEUTICALS) at 5/7/2015. The price target of $13 was fulfilled within 1 day with a profit of $0.35 (2.77%) receiving and performance score of 27.67.

Average potential price target upside

of $66.74 (55.2%) on AMGN (AMGEN).
of $44.16 (87.98%) on GILD (GILEAD SCIENCES).
of $39.4 (13.22%) on BIIB (BIOGEN).

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical CELG Celgene GILD Gilead Sciences INCY yte NBIX Neurocrine Biosciences TTPH Tetraphase Pharmaceuticals ICPT Intercept Pharmaceuticals CHRS Coherus BioSciences INFI Infinity Pharmaceuticals MYOK MyoKardia PTGX Protagonist Therapeutics

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score